EGFR is an oncogene that is frequently amplified in glioblastoma. A new study suggests a tumour-suppressive role of EGFR in EGFR-amplified glioblastoma regulated by ligand abundance. Increased EGFR ligand in EGFR-amplified glioblastoma suppresses invasion by upregulating BIN3 and inhibiting activation of Rho GTPases.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Louis, D. N. et al. Neuro Oncol. 23, 1231–1251 (2021).
Dirks, P. B. et al. Clin. Cancer Res. 26, 2457–2460 (2020).
Brennan, C. W. et al. Cell 155, 462–477 (2013).
Fan, Q. W. et al. Cancer Cell 24, 438–449 (2013).
Chakraborty, S. et al. Nat. Commun. 5, 5811 (2014).
Singh, B. et al. F1000 Res. https://doi.org/10.12688/f1000research.9025.1 (2016).
Hu, C. et al. Nature 602, 518–522 (2022).
Guo, G. et al. Nat. Cell Biol. https://doi.org/10.1038/s41556-022-00962-4 (2022).
An, Z. et al. Oncogene 37, 1561–1575 (2018).
de Vries, N. A. et al. Invest. New Drugs 30, 443–449 (2012).
Barkovich, K. J. et al. Cancer Discov. 2, 450–457 (2012).
Ramnarain, D. B. et al. Cancer Res. 66, 867–874 (2006).
Prendergast, G. C. et al. Biochim. Biophys. Acta 1796, 25–36 (2009).
Murray, D. W. et al. Br. J. Cancer 110, 1307–1315 (2014).
Ramnarain, D. B. et al. Cancer Res. 66, 867–874 (2006).
Le Rhun, E. et al. Cancer Treat. Rev. 80, 101896 (2019).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing interests.
Rights and permissions
About this article
Cite this article
Beytagh, M.C., Weiss, W.A. EGFR ligands dictate tumour suppression. Nat Cell Biol 24, 1189–1191 (2022). https://doi.org/10.1038/s41556-022-00967-z
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41556-022-00967-z